168 related articles for article (PubMed ID: 30485488)
1. First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats.
Takakura S; Takasu T
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):266-273. PubMed ID: 30485488
[TBL] [Abstract][Full Text] [Related]
2. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
Takakura S; Takasu T
Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
[TBL] [Abstract][Full Text] [Related]
3. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
Takakura S; Toyoshi T; Hayashizaki Y; Takasu T
Life Sci; 2016 Feb; 147():125-31. PubMed ID: 26829386
[TBL] [Abstract][Full Text] [Related]
4. Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.
Takasu T; Takakura S
Life Sci; 2019 Aug; 230():19-27. PubMed ID: 31125563
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):423-36. PubMed ID: 22139434
[TBL] [Abstract][Full Text] [Related]
6. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
[TBL] [Abstract][Full Text] [Related]
8. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharmacol Sci; 2012; 120(1):36-44. PubMed ID: 22971845
[TBL] [Abstract][Full Text] [Related]
10. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
Tahara A; Kondo Y; Takasu T; Tomiyama H
Biomed Pharmacother; 2018 Sep; 105():1033-1041. PubMed ID: 30021338
[TBL] [Abstract][Full Text] [Related]
11. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Tahara A; Takasu T
Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076
[TBL] [Abstract][Full Text] [Related]
12. The Role of SGLT2 Inhibitor Ipragliflozin on Cardiac Hypertrophy and microRNA Expression Profiles in a Non-diabetic Rat Model of Cardiomyopathy.
Takasu T
Biol Pharm Bull; 2022; 45(9):1321-1331. PubMed ID: 36047201
[TBL] [Abstract][Full Text] [Related]
13. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
Sakaeda T; Kobuchi S; Yoshioka R; Haruna M; Takahata N; Ito Y; Sugano A; Fukuzawa K; Hayase T; Hayakawa T; Nakayama H; Takaoka Y; Tohkin M
Int J Med Sci; 2018; 15(9):937-943. PubMed ID: 30008607
[No Abstract] [Full Text] [Related]
15. SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice.
Tahara A
Eur J Pharmacol; 2021 Nov; 910():174486. PubMed ID: 34487707
[TBL] [Abstract][Full Text] [Related]
16. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
[TBL] [Abstract][Full Text] [Related]
17. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Tahara A; Takasu T
Naunyn Schmiedebergs Arch Pharmacol; 2018 Apr; 391(4):395-406. PubMed ID: 29374293
[TBL] [Abstract][Full Text] [Related]
18. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Nishimura N; Kitade M; Noguchi R; Namisaki T; Moriya K; Takeda K; Okura Y; Aihara Y; Douhara A; Kawaratani H; Asada K; Yoshiji H
J Gastroenterol; 2016 Dec; 51(12):1141-1149. PubMed ID: 27025708
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
Kaku K; Isaka H; Toyoshima J; Sakatani T
Diabetes Obes Metab; 2019 Jun; 21(6):1445-1454. PubMed ID: 30821047
[TBL] [Abstract][Full Text] [Related]
20. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
Masuda T; Muto S; Fukuda K; Watanabe M; Ohara K; Koepsell H; Vallon V; Nagata D
Physiol Rep; 2020 Jan; 8(2):e14360. PubMed ID: 31994353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
